A phase 1b/2 study on ribociclib plus trastuzumab or T-DM1 in patients with advanced HER2-positive breast cancer previously treated with trastuzumab, pertuzumab, and T-DM1 was conducted (112). The gene discussed is ERBB2; the disease is breast cancer.